A multidisciplinary group of tuberculosis experts from the TBnet and RESIST-TB networks have reached a consensus on key issues related to the molecular prediction of Mycobacterium tuberculosis antibiotic sensitivity or resistance and its clinical implications. The consensus document provides guidance for the design of therapeutic regimens and the optimization of treatments, and is intended to help clinicians manage tuberculosis patients. The paper, published in The Lancet Infectious Diseases and led by Dr José Domínguez from the Germans Trias i Pujol Research Institute (IGTP), is an update of a similar statement made in 2016. The publication presents a review of the current tools to rapidly identify resistance to drugs used in the treatment of tuberculosis. Read more here.
top of page
Recent Posts
See AllThe results of the TB-CHAMP trial were recently published. They showed that prophylactic levofloxacin can significantly reduce the risk...
50
This month, the Indian Patent Office denied the last of the three Janssen patent extension applications for bedaquiline. While TB...
10
The Institute of Tropical Medicine has announced two initiatives to honor the legacy of Armand Van Deun: a new meeting room in his name...
430
bottom of page
Commentaires